Vyndamax

Active Ingredient(s): Tafamidis
FDA Approved: * May 3, 2019
Pharm Company: * FOLDRX PHARMS
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Vyndamax Overview

Tafamidis (trade name Vyndaqel)[1] is a drug used to delay loss of peripheral nerve function in adults with familial amyloid polyneuropathy (FAP), an orphan disease. It works by stabilizing the protein, transthyretin, which is normally made up of four strands. In people with FAP these strands separate and form clumps that harm nerves. In May 2019, the FDA approved two preparations tafamidis meglumine and tafamidis, for the treatment of transthyretin mediated cardiomyopathy ...

Read more Vyndamax Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tafamidis

Recent Vyndamax Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Vyndamax: (1 result)

Sorted by National Drug Code

• 0069-8730 Vyndamax 61 mg Oral Capsule, Liquid Filled by Pfizer Laboratories Div Pfizer Inc

Other drugs which contain Tafamidis or a similar ingredient: (2 results)

• TAFAMIDIS
• VYNDAQEL Tafamidis Meglumine